Abstract
Abstract only
- Title
- GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer
- Creators
- Krishnansu Sujata Tewari - University of California, IrvineIgnace Vergote - Gynaecological Oncology, Leuven Cancer Institute, Leuven, BelgiumAna Oaknin - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainEdwin Alvarez - UCSF Helen Diller Family Comprehensive Cancer CenterDana Meredith Chase - Creighton UniversityStephanie Gaillard - Departments of Oncology & Gynecology & Obstetrics, Johns Hopkins School of Medicine, Baltimore, MDStephanie Lheureux - Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CanadaDanny Rischin - Peter MacCallum Cancer CentreAlessandro Santin - Yale UniversityMinjie Feng - RegeneronMelissa Mathias - RegeneronMatthew G. Fury - RegeneronIsrael Lowy - RegeneronBradley J. Monk - Creighton University
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.TPS5600-TPS5600
- Identifiers
- 991005968873002656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article